Dr. Michael Burke is an Associate Professor at the Children’s Hospital of Wisconsin (CHW) in the Division of Hematology/Oncology/Blood & Marrow Transplantation. He is Director of the Pediatric Leukemia & Lymphoma Program at CHW and Co-Director of the Developmental Therapeutics Program where he oversees all early phase clinical trials (Phase I and II studies) at CHW. He has developed both early phase and upfront clinical trials in acute leukemia that have opened locally here at CHW as well as nationally and internationally through consortiums such as the Children’s Oncology Group (COG) and the Therapeutic Advances in Childhood Leukemia & Lymphoma Consortium (TACL). Dr. Burke is the principal investigator of a Phase I trial for relapsed ALL and a phase I trial in relapsed AML both through the TACL consortium as well as study chair for the upfront COG trial for children with High-Risk and Very High-Risk B-cell ALL.
Dr. Burke’s research interests have focused on reporting clinical outcomes for both children and adults with high-risk leukemia for which he has over 30 publications as well as the development of early phase clinical trials investigating novel agents and/or combination therapies for relapsed/refractory acute leukemia. He did his pediatric residency at the Medical College of Virginia /Virginia Commonwealth University in Richmond Virginia and pediatric fellowship training in hematology-oncology at Northwestern University Lurie Children’s Hospital in Chicago Illinois.
Pediatric Hematology-Oncology, Pediatrics - General
2012 - Present Member, TACL Steering & Prioritization Committee, Medical College of Wisconsin
2012 - Present Member, TACL Steering Committee, Medical College of Wisconsin
2011- Present Study co-chair, AALL1131 A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789) NSC#606869) in the Very High Risk Stratum, Children’s Oncology Group (COG)
2010- 2013 Study Chair, ADVL0911 Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-011), Children’s Oncology Group (COG)
2010- 2012 Committee Member, ALL Relapse Task Force, Children’s Oncology Group (COG)
2009 - Present Study Chair, TACL T2009-003, A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL